Solid Biosciences (NASDAQ:SLDB) Posts Earnings Results

20 Mar 2026, 07:12 by Renee Jackson · The Cerbat Gem

Solid Biosciences (NASDAQ:SLDB – Get Free Report) released its quarterly earnings data on Thursday. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.05), FiscalAI reports.

Solid Biosciences Price Performance

Solid Biosciences stock opened at $7.12 on Friday. Solid Biosciences has a 52 week low of $2.41 and a 52 week high of $8.72. The company’s 50 day moving average price is $6.40 and its two-hundred day moving average price is $5.78. The stock has a market cap of $554.72 million, a P/E ratio of -2.86 and a beta of 2.65.

Wall Street Analysts Forecast Growth

SLDB has been the topic of a number of analyst reports. Citigroup restated a “market outperform” rating on shares of Solid Biosciences in a report on Wednesday, December 17th. Wedbush reiterated an “outperform” rating and set a $14.00 price target on shares of Solid Biosciences in a research note on Wednesday, March 11th. Needham & Company LLC reissued a “buy” rating and set a $16.00 price objective on shares of Solid Biosciences in a report on Monday, February 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Solid Biosciences in a research note on Thursday, January 22nd. Finally, Chardan Capital restated a “buy” rating and issued a $15.00 target price on shares of Solid Biosciences in a report on Thursday, March 12th. Ten investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $14.70.

Check Out Our Latest Stock Analysis on SLDB

Insider Buying and Selling

In other Solid Biosciences news, insider Gabriel Brooks sold 28,335 shares of the business’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $6.44, for a total value of $182,477.40. Following the transaction, the insider owned 96,708 shares of the company’s stock, valued at approximately $622,799.52. The trade was a 22.66% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO David T. Howton sold 37,771 shares of the company’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $6.44, for a total value of $243,245.24. Following the completion of the transaction, the chief operating officer owned 116,753 shares of the company’s stock, valued at $751,889.32. This trade represents a 24.44% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 597,672 shares of company stock valued at $3,816,546 over the last quarter. Corporate insiders own 1.90% of the company’s stock.

Institutional Investors Weigh In On Solid Biosciences

A number of hedge funds have recently made changes to their positions in SLDB. Legal & General Group Plc grew its position in Solid Biosciences by 208.6% during the second quarter. Legal & General Group Plc now owns 6,011 shares of the company’s stock valued at $29,000 after buying an additional 4,063 shares during the period. Creative Planning bought a new stake in Solid Biosciences in the second quarter worth about $57,000. Russell Investments Group Ltd. raised its position in Solid Biosciences by 142.0% in the third quarter. Russell Investments Group Ltd. now owns 10,211 shares of the company’s stock worth $63,000 after acquiring an additional 5,991 shares during the period. Polymer Capital Management US LLC purchased a new position in Solid Biosciences in the third quarter valued at about $94,000. Finally, Jain Global LLC purchased a new position in Solid Biosciences in the fourth quarter valued at about $114,000. 81.46% of the stock is currently owned by institutional investors.

Solid Biosciences Company Profile

(Get Free Report)

Solid Biosciences Inc is a clinical‐stage biotechnology company focused on the development of therapies for Duchenne muscular dystrophy (DMD), a rare genetic disorder characterized by progressive muscle degeneration. The company’s primary approach centers on gene replacement and gene editing technologies designed to restore functional dystrophin protein in patients lacking this critical muscle‐stabilizing protein.